Uveitis as a Result of MAP Kinase Pathway Inhibition | Zendy

Lavnish Joshi | Zendy; Andreas Karydis | Zendy; Maria Gemenetzi | Zendy; Emily H. Shao | Zendy; Simon Taylor | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Uveitis as a Result of MAP Kinase Pathway Inhibition

Author(s) -

Lavnish Joshi,

Andreas Karydis,

Maria Gemenetzi,

Emily H. Shao,

Simon Taylor

Publication year - 2013

Publication title -

case reports in ophthalmology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.299

H-Index - 17

ISSN - 1663-2699

DOI - 10.1159/000357060

Subject(s) - medicine , trametinib , dabrafenib , uveitis , melanoma , mapk/erk pathway , protein kinase a , mitogen activated protein kinase , side effect (computer science) , dermatology , kinase , cancer research , immunology , metastatic melanoma , vemurafenib , biology , microbiology and biotechnology , computer science , programming language

We report the case of a patient treated with dabrafenib and trametinib (mitogen-activated protein kinase pathway inhibitors) for stage 3b cutaneous melanoma who developed bilateral uveitis. Although there have been reports of ocular side effects with this class of drugs, uveitis has not been previously reported to the best of our knowledge. This case indicates the wide range of side effects that can be seen with the newer targeted biological therapies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research